2022 represented a strategic inflection point for Vertex and its core mission of investing in scientific innovation to create transformative medicines for people with serious diseases. Execution on its unique and differentiated strategy, combined with its special culture enabled broader access to its cystic fibrosis (CF) medicines across the globe, fueled significant advances in multiple diseases across its pipeline, and created more ways to positively impact patients, employees and its communities.
Vertex’s unique strategy, values, talented employees, and its culture of innovation and inclusion will continue to fuel long-term success as they continue their journey in CF, prepare for commercial launches in multiple serious diseases, and drive and accelerate the research pipeline forward, all while continuing to operate its business responsibly.
Contact:
Sarah D’Souza, 857-329-8495
In their newly released 2022 annual Corporate Responsibility report, Vertex highlights the progress made with respect to its environmental, social and governance (ESG) efforts.
